INC Research CEO reflects on Kendle acquisition

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

INC Research CEO reflects on Kendle acquisition
INC Research CEO James Ogle tells Outsourcing-pharma.com that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.

The $232m (€165m) acquisition of Kendle earlier​ this month gives INC a presence in Latin America and Asia, broadens its therapeutic reach and provides an expanded customer base according to Ogle.

The key thing here is we are looking at ‘Where is drug development going?’ And, I think the most important thing is that our customers are looking at developing drugs in areas where the ultimately hope to sell them​.”

Ogle also set out INC’s integrations strategy, explaining that the policy is to look for the best person for a particular role “regardless of what legacy part of the business they come from​.”

He also spoke about the firm’s track record of acquisitions – MDS Pharma Services late-stage unit and Trident – and said that while no further takeovers are planned if the correct opportunity arises INC will consider further deals.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars